Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Find out which cash back cards come with no annual fees. Maximize your savings and enjoy great rewards!
27,891 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Tesla sits at a fair-value crossroads in 2026, with capex and AI initiatives guiding a modest upside. Here’s how inve...
Barclays has boosted its Ionis target to $106, signaling a roughly 46% upside from recent levels as olezarsen eyes pe...
In 2026, Nvidia stock has cooled from its sky-high run. If you own NVDA, you’ll want a clear plan: trim profits, reba...
Unity Software’s latest guidance sparked a sharp rally, underscoring how Vector AI could redefine monetization in int...
A late-life mortgage decision that looked smart on math may falter when survivorship risk hits the household budget. ...
Argan stock ascended today as investors cheered stronger profits and a brighter outlook for energy infrastructure tie...
When a CEO sells thousands of shares, investors want to know what it signals. This guide explains how to read insider...
MP Materials is catching investor attention again in 2026 as policy support, domestic production efforts, and a risin...
Fastenal is delivering steady, long‑term gains through an embedded, service‑driven model. Here’s why the stock fits a...
In the first five months of 2026, luxury buyer interest doubles in the U.S. luxury market, with buyers favoring large...
Apple is taking a guarded AI route, leaning on partnerships and modest capex. The strategy could alter AI investing d...